189 related articles for article (PubMed ID: 25659029)
1. Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma.
Hernández Fernández de Rojas D; Antépara Ercoreca I; Ponte Tellechea A; Ibáñez Echevarría E; Jáuregui Presa I; Gamboa Setién P; Asturias JA; Landeta Manzano A; Madariaga Goirigolzarri B
Immunotherapy; 2015; 7(2):89-99. PubMed ID: 25659029
[TBL] [Abstract][Full Text] [Related]
2. Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy.
Moreno V; Alvariño M; Rodríguez F; Roger A; Peña-Arellano MI; Lleonart R; Pagán JA; Navarro JA; Navarro LA; Vidal C; Ponte-Tellechea A; Gómez-Fernández MC; Madariaga-Goirigolzarri B; Asturias JA; Hernández-Fernandez de Rojas D
Immunotherapy; 2016; 8(3):265-77. PubMed ID: 26757045
[TBL] [Abstract][Full Text] [Related]
3. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
4. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
[TBL] [Abstract][Full Text] [Related]
5. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy.
Tabar AI; González Delgado P; Sánchez Hernández C; Basagaña Torrento M; Moreno Benítez F; Arina M
J Investig Allergol Clin Immunol; 2015; 25(1):40-6. PubMed ID: 25898693
[TBL] [Abstract][Full Text] [Related]
6. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
7. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.
Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F
J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782
[TBL] [Abstract][Full Text] [Related]
8. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
[TBL] [Abstract][Full Text] [Related]
9. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
[TBL] [Abstract][Full Text] [Related]
10. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
Liu Y; Xing Z; Wang J; Geng C
Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
[TBL] [Abstract][Full Text] [Related]
11. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
[TBL] [Abstract][Full Text] [Related]
12. [Safety of subcutaneous immunotherapy with tyrosine-adsorbed house dust mite extracts in patients with allergic disease].
Molina-Sáenz MM; Villa-Arango AM; Cardona-Villa R
Rev Alerg Mex; 2017; 64(1):52-65. PubMed ID: 28188713
[TBL] [Abstract][Full Text] [Related]
13. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma.
Pfaar O; Klimek L; Sager A; Bräutigam M
Am J Rhinol Allergy; 2010; 24(3):220-5. PubMed ID: 20167138
[TBL] [Abstract][Full Text] [Related]
14. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
[TBL] [Abstract][Full Text] [Related]
16. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study.
García-Robaina JC; Sánchez I; de la Torre F; Fernández-Caldas E; Casanovas M
J Allergy Clin Immunol; 2006 Nov; 118(5):1026-32. PubMed ID: 17088125
[TBL] [Abstract][Full Text] [Related]
17. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.
Ameal A; Vega-Chicote JM; Fernández S; Miranda A; Carmona MJ; Rondón MC; Reina E; García-González JJ
Allergy; 2005 Sep; 60(9):1178-83. PubMed ID: 16076305
[TBL] [Abstract][Full Text] [Related]
18. Changes in IL-10 and specific antibodies associated to successful Dermatophagoides pteronyssinus immunotherapy in children during the first year of treatment.
Martín-Muñoz MF; Pineda F; Muiños T; Fontan M; Nevot S; Bosque M; Jurado Palomo J; Torredemer A; Valdesoiro L; Martinez Cañavate AM; Pedemonte Marco C;
Allergol Immunopathol (Madr); 2013; 41(1):4-10. PubMed ID: 22321665
[TBL] [Abstract][Full Text] [Related]
19. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
